Guanidine-Based Polymer Microbicide for HPV and HSV Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral treatments for human papillomaviruses (HPV) and herpes simplex viruses (HSV) are inadequate, as they do not effectively prevent or treat infections, particularly at the early stages, and existing vaccines and therapies are limited in their scope and accessibility, especially for high-risk HPV types and HSV infections.
Innovation Solution
Development of guanidine-based poly(amido-amine) polymers, such as AGMA-1, which exhibit potent antiviral activity against HPV-16 and HSV-1/HSV-2, inhibiting viral infections by targeting early stages of the viral lifecycle, and can be formulated into pharmaceutical compositions for various administration routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines are used to prevent HPV infections, then protection against targeted HPV types is achieved, but coverage is limited to specific types and requires administration before sexual activity
Solution Approach 1:
The patent describes a topical microbicide formulation that provides broad-spectrum protection against multiple HPV types simultaneously, unlike type-specific vaccines. The microbicide contains antiviral agents that can prevent infection by various high-risk and low-risk HPV types through a single application, making the protection universal across different virus strains.
Solution Approach 2:
The microbicide is designed to be applied topically to create a protective barrier at the portal of entry before viral infection can establish. This preliminary protective action can be taken at any time, not just before sexual activity like vaccines require, allowing flexible prevention timing while blocking viral entry and early replication.
2Reliability
If vaccines are used for HPV prevention, then immunization against targeted types is achieved, but cost becomes prohibitive for underdeveloped countries
Solution Approach 1:
The microbicide is formulated as a topical application that can be locally manufactured and distributed at lower cost compared to vaccine production. The formulation uses accessible pharmaceutical ingredients and standard excipients that can be produced in underdeveloped countries, making the prevention tool economically accessible without requiring complex cold chain storage or specialized manufacturing facilities.
3Ease of operation
If topical microbicide is used to block HPV at portal of entry, then prevention of infection is achieved, but effectiveness against established infections is limited
Solution Approach 1:
The microbicide is optimized to act at the portal of entry by forming a protective barrier on mucosal surfaces that prevents viral attachment and entry into cells. This preliminary blocking action is most effective when applied before viral exposure, creating a preventive shield that stops infection before it can establish in the host tissue.
Solution Approach 2:
The formulation includes antiviral agents at concentrations sufficient to provide robust preventive protection against viral infection. The excess antiviral activity in the formulation ensures complete blocking of viral entry, prioritizing prevention efficacy over treatment of established infections where viral replication may already be advanced.
4Productivity
If acyclovir is used to treat HSV infection, then viral replication is reduced, but the virus cannot be eradicated from infected cells
Solution Approach 1:
The microbicide formulation targets the earliest stages of viral infection by blocking viral attachment and entry into host cells before replication begins. By acting at this preliminary stage, the formulation prevents the establishment of infection in the first place, rather than merely controlling replication after infection has already occurred in the cells.
Data Source
AI summary
Guanidine-based poly (amidoamine) polymers of formula (I): wherein n is an integer between 3 and 400; R1 is H, C1-6 alkyl; or taken together with the N atoms to which is bound and R2 is a piperazinic ring; R2 is C2-6 alkylen; C5-6 cycloalkylen; CH—COOH, CH—COOR, wherein R is C1-4 alkyl, phenyl or benzyl; R3 is —(CH2)p-HN—C(NH2)═NH, wherein p is an integer 1 to 6; for use as antiviral agents in the prevention and/or treatment of viral infections in a mammal, preferably a human subject.